Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 years at the index date. 2. Unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). 3. Documented HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutation. 4. Received at least one prior systemic therapy for advanced NSCLC. Prior HER2-targeted antibody-drug conjugate (ADC) therapy is permitted, whereas prior HER2-targeted tyrosine kinase inhibitor (TKI) therapy is not permitted. 5. For retrospectively included participants, sufficient baseline clinical, treatment, and prior follow-up data are available. 6. Sevabertinib treatment has been determined by the treating physician based on clinical practice, or the participant has already initiated sevabertinib at screening. Exclusion Criteria: 1. History of Grade 3 or higher interstitial lung disease (ILD), or evidence of any clinically active ILD. 2. Uncontrolled comorbid diseases or conditions, including but not limited to decompensated respiratory, cardiac, hepatic, or renal disease; ongoing or active infection, including active clinical tuberculosis; renal transplantation; or psychiatric/social conditions that may limit study compliance. 3. Unstable brain metastases. 4. Inability to comply with the study for any reason. 5. Receipt of another unapproved investigational drug or non-drug treatment within 30 days before the index date or during the observation period.